Wednesday, September 09, 2020 OV19: A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) In Patients with Epithelial Ovarian Cancer González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 152: 53-60, 2019. Objectives:To compare the progression-free survival and overall survival of patients with newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer treated with carboplatin and paclitaxel with vs without bevacizumab. OV19 Publication: https://www.sciencedirect.com/science/article/pii/S0090825818311661?via%3Dihub JBR10: Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10 Grieve S, Ding K, Moore J, Finniss M, Ray A, Lees M, Hossain F, Murugesan A, Agar J, Acar C, Taylor J, Shepherd FA, Reiman T. Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10. ESMO Open 5: e000679, 20 A.D. Objective: There are no validated approaches to predict benefit from adjuvant chemotherapy for resected patients with non-small-cell lung cancer (NSCLC). The aim of this study was to translate a 15-gene mRNA expression profile published by Zhu et al, shown to be prognostic and predictive of benefit, into a readily applicable immunohistochemistry (IHC) panel. Publication: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174014/ MAP3: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer Ho V, Pasquet R, Luo S, Chen G, Goss P, Tu D, Lazarus P, Richardson H. Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial (ONLINE). Breast Cancer Res Treat 2020. Objectives: To determine if exemestane reduces the incidence of invasive breast cancer compared with placebo. Publication: https://link.springer.com/article/10.1007%2Fs10549-020-05812-1 CE6: A Randomized Phase III Study Of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Climans SA, Brandes AA, Cairncross JG, Ding K, Fay M, Laperriere N, Menten J, Nishikawa R, O'Callaghan CJ, Perry JR, Phillips C, Roa W, Wick W, Winch C, Mason WP. Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. Journal of Neuro-Oncology 149: 65-71, 2020. Objective: To compare overall survival rates in older patients with newly diagnosed glioblastoma multiforme treated with short-course radiotherapy with or without temozolomide. CE6 Publication: https://link.springer.com/article/10.1007%2Fs11060-020-03573-x BR18: A Phase II/III Double Blind Randomized Trial of BMS-275291 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Hao D, Sengupta A, Ding K, Ubeydullah ER, Krishnaiah S, Leighl NB, Shepherd FA, Seymour L, Weljie A. Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy. Cancers 12: 2020. Objectives: To compare the overall survival of patients with advanced or metastatic non-small cell lung cancer treated with paclitaxel and carboplatin with or without BMS-275291. Compare the incidence of grade 2 or higher drug related arthritis, arthralgia and/or myalgia in patients treated with these regimens. (Phase II only). Compare the objective tumor response rate, time to response, and response duration in patients treated with these regimens. Compare the nature, severity, and frequency of toxic effects of these regimens in these patients. Compare the progression free survival of patients treated with these regimens. (Phase III only). Correlate the expression of serum/plasma and tissue matrix metalloproteinases (MMP) levels and other markers with outcomes and response in patients treated with these regimens. Compare quality of life of patients treated with these regimens. BR18 Publication: https://www.mdpi.com/2072-6694/12/7/1926/htm
